Clinical Trials · NCT01754285
Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Chemi S.p.A.
- Enrollment
- 114
- Start date
- Nov 2012
- Locations
- 13 sites, Italy
- Primary endpoint
- effect of LF-PB 10 mg, 20 mg, and 30 mg on time to resolution of lymphorrhea;